VivoSeq
Ophthalmology

Cataract

150

Pipeline Programs↗

42

Active Trials↗

49

Companies Involved↗

Cataract is a highly competitive landscape with 150 programs across 49 companies. The most active players are Melt Pharmaceuticals, Formosa Pharmaceuticals, Inc., VivaVision Biotech, Inc. 60 therapies are approved with 28 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

51/100

Mech. Concentration

13/100

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Melt Pharmaceuticals

3 programs

Phase 2F

Formosa Pharmaceuticals, Inc.

1 program

Phase 2V

VivaVision Biotech, Inc

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2N

Nacuity Pharmaceuticals, Inc.

1 program

Phase 2O

Othera Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical30

Norepinephrine

General Hospital of Ningxia Medical University

Triamcinolone

Bassett Healthcare

Bimatoprost

AbbVie

Lidocaine

MEDRx USA, Inc.

Epinephrine

Samson Clinical Operations Pty Ltd

Phase 14

Ranibizumab

Roche

Reference Listed Drug (RLD)

Novartis

Generic Tacrolimus

Novartis

Hydroxypropyl Methylcellulose

University of California, San Francisco

Phase 228

Clonidine

Boehringer Ingelheim

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cyclopentolate

KK Women's and Children's Hospital

Nalbuphine

Aultman Health Foundation

Denufosol Tetrasodium (INS37217)

Merck & Co.

Phase 328

Prednisolone Acetate

Novartis

Loteprednol Etabonate

Bausch & Lomb Incorporated

Ketorolac

Javelin Pharmaceuticals

Aspirin

Bayer

Bevacizumab

Bio-Thera Solutions

Approved60

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ketorolac Tromethamine

Roche

Ketamine

Aultman Health Foundation

Propofol

Fresenius Kabi Oncology Ltd.

Acetylcholine

Bausch Health Americas, Inc.

Analysis

Modality Breakdown

98%

Small molecule

213 of 218 classified programs — the dominant modality here.

2%ALL OTHERSProtein / enzyme31%Monoclonal antibody2<1%

Small molecule leads; the ring shows all 218 classified programs, each share of the total. Modality classified for 100% of 220 pipeline programs.

Analysis

Trial Status

257

clinical trials

Completed167 · 65%
Recruiting26 · 10%
Unknown status23 · 9%
Terminated16 · 6%
Not yet recruiting12 · 5%
Withdrawn9 · 4%
Other4 · 2%

Clinical Trials

Trial Activity

257 trials

Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery
Recruiting·SSuez Canal University·Phase 3·NCT07080229·126 enrolled
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT05157113·70 enrolled
Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety
Recruiting·NNational Taiwan University Hospital·N/A·NCT06826417·400 enrolled
Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT04050644·100 enrolled
An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANAX) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06874452·250 enrolled
Oral vs IV Sedation for Cataract Surgery in Older Adults
Recruiting·UUniversity of California, San Francisco·Phase 4·NCT07154147·20 enrolled
Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06886373·140 enrolled
The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery
Recruiting·SSingapore Eye Research Institute·Phase 3·NCT06048380·120 enrolled
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
Recruiting·BBerkeley Eye Center·Phase 4·NCT06922084·320 enrolled
Effect of Vitamin C Supplementation in Corneal Endothelial Damage in Phacoemulsification of Patients with Hard Cataracts
Recruiting·IIndonesia University·N/A·NCT06781970·120 enrolled
PRO-232 in Patients Subjected to Cataract Surgery
Recruiting·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT07305987·134 enrolled
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
Recruiting·—·N/A·NCT07178639·150 enrolled
Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06763731·150 enrolled
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Recruiting·MMelt Pharmaceuticals·Phase 3·NCT06383273·528 enrolled
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Recruiting·EEyePoint Pharmaceuticals, Inc.·Phase 4·NCT05191706·60 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)